Compare MCHP & GEHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MCHP | GEHC |
|---|---|---|
| Founded | 1989 | 1892 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Computer Software: Prepackaged Software |
| Sector | Technology | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.1B | 33.1B |
| IPO Year | 1993 | N/A |
| Metric | MCHP | GEHC |
|---|---|---|
| Price | $67.17 | $83.83 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 21 | 9 |
| Target Price | $74.43 | ★ $86.67 |
| AVG Volume (30 Days) | ★ 9.9M | 4.2M |
| Earning Date | 11-06-2025 | 10-29-2025 |
| Dividend Yield | ★ 2.71% | 0.17% |
| EPS Growth | N/A | ★ 32.35 |
| EPS | N/A | ★ 4.83 |
| Revenue | $4,212,399,999.00 | ★ $20,246,000,000.00 |
| Revenue This Year | $5.14 | $6.33 |
| Revenue Next Year | $19.01 | $4.38 |
| P/E Ratio | ★ N/A | $17.38 |
| Revenue Growth | N/A | ★ 3.51 |
| 52 Week Low | $34.13 | $57.65 |
| 52 Week High | $77.20 | $94.80 |
| Indicator | MCHP | GEHC |
|---|---|---|
| Relative Strength Index (RSI) | 65.34 | 61.25 |
| Support Level | $66.23 | $83.56 |
| Resistance Level | $69.56 | $86.19 |
| Average True Range (ATR) | 2.23 | 2.22 |
| MACD | 1.44 | 0.32 |
| Stochastic Oscillator | 86.09 | 71.87 |
Microchip Technology became an independent company in 1989 when it was spun off from General Instrument. More than half of revenue comes from MCUs, which are used in a wide array of electronic devices from remote controls to garage door openers to power windows in autos. The company's strength lies in lower-end 8-bit MCUs that are suitable for a wider range of less technologically advanced devices, but the firm has expanded its presence in higher-end MCUs and analog chips as well.
GE HealthCare Technologies is a leading medical technology firm with leading market share in imaging and ultrasound equipment. The company reports four major segments: imaging (45% of revenue), advanced visualization solutions (26%), patient care solutions (16%), and pharmaceutical diagnostics (13%). The company's sales are geographically diverse, with the United States, EMEA, China, and the rest of the world accounting for 46%, 26%, 12%, and 17% respectively. We estimate approximately half of its revenue is recurring, which consists of servicing (about one third of revenue), pharmaceutical diagnostics (about 10%-15%), and digital solutions (just over 5%).